Bio

Clinical Focus


  • Pediatric Endocrinology
  • Pediatric Endocrinology & Diabetes

Academic Appointments


Administrative Appointments


  • Clinical Instructor/Clinician Educator, Pediatric Endocrinology & Diabetes (2012 - Present)

Honors & Awards


  • Pediatric Sponsored Fellowship Award - Siegelman Award, Stanford University (2010-2012)
  • Dean's Postdoctoral Fellowship Award, Stanford University (2010-2011)
  • Stanford Society of Physician Scholars, Member, Stanford University (2010-present)
  • LPCH Endowed Clinical Fellow in Endocrinology, Stanford University (2009-2010)

Professional Education


  • Internship:Rainbow Babies And Childrens (2006) OH
  • Residency:Rainbow Babies And Childrens (2008) OH
  • Fellowship:Stanford University - Dept of Pediatrics (2012) CA
  • Board Certification: Pediatrics, American Board of Pediatrics (2008)
  • Medical Education:Northwestern University Medical School (2005) IL
  • Board Certificiation, American Board of Pediatrics, General Pediatrics (2008)

Research & Scholarship

Current Research and Scholarly Interests


My primary research interest is evaluating whether vitamin D supplementation can positively affect consequences of the metabolic syndrome in overweight and obese adolescents. Other research interests include evaluating the efficacy and biochemical profiles of various types of estrogen replacement in adolescent females.

Clinical Trials


  • Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure Not Recruiting

    To directly compare the safety (by laboratory evaluation) and efficacy (feminization and growth) of three commonly used estrogen preparations in adolescent patients with ovarian failure, either due to congenital causes (Turner syndrome) or medical therapies. We hypothesize that transdermal estrogen will have equivalent efficacy and a more favorable safety profile in comparison with conventional oral estrogen replacement.

    Stanford is currently not accepting patients for this trial. For more information, please contact Sejal Shah, (650) 723 - 5791.

    View full details

  • Effect of Vitamin D Supplementation on Inflammation and Cardiometabolic Risk Factors in Obese Adolescents Not Recruiting

    Large studies of children show that over half of the children in the United States of America do not have enough vitamin D stored in their bodies. In children who are overweight or obese, the percentage of children who do not have enough vitamin D is even higher. Vitamin D is essential for the body to maintain normal calcium levels and strong bones. Recent research shows that through the actions of inflammatory markers, levels in the blood that measure inflammation in the body, vitamin D plays many other important roles in the body like helping to regulate the immune system, blood sugar levels, blood pressure, and body fat. The purpose of this study is to determine the effect of vitamin D supplementation on inflammatory markers in obese and overweight adolescents. As a secondary goal, we would like to evaluate cardiometabolic risk factors and the correlation between body mass index, vitamin D stores and inflammatory cytokines. In an observed, randomized controlled trial over 6 months we will provide observed vitamin D supplementation or placebo to healthy obese and overweight adolescents and measure changes in inflammatory markers, lipids, blood pressure, and mean blood sugars. We hypothesize that administration of vitamin D to these patients will improve their inflammatory profile and cardiometabolic risk factors (blood glucose, blood pressure, and lipid profile).

    Stanford is currently not accepting patients for this trial. For more information, please contact Sejal Shah, (650) 723 - 5791.

    View full details

Publications

Journal Articles


  • Newborn with prenatally diagnosed choroidal fissure cyst and panhypopituitarism and review of the literature. AJP reports Chitkara, R., Rajani, A., Bernstein, J., Shah, S., Hahn, J. S., Barnes, P., Hintz, S. R. 2011; 1 (2): 111-114

    Abstract

    Little has been reported on fetal diagnosis of choroidal fissure cysts and prediction of the clinical complications that can result. We describe the case of a near-term male infant with prenatally diagnosed choroidal fissure cyst and bilateral clubfeet. His prolonged course in the neonatal intensive care nursery was marked by severe panhypopituitarism, late-onset diabetes insipidus, placement of a cystoperitoneal shunt, and episodes of sepsis. Postnatal genetic evaluation also revealed an interstitial deletion involving most of band 10q26.12 and the proximal half of band 10q26.13. The patient had multiple readmissions for medical and surgical indications and died at 6 months of age. This case represents the severe end of the spectrum of medical complications for children with choroidal fissure cysts. It highlights not only the importance of comprehensive evaluation and multidisciplinary management and counseling in such cases, but also the need for heightened vigilance in these patients.

    View details for DOI 10.1055/s-0031-1293512

    View details for PubMedID 23705098

  • Interaction of PIMT with transcriptional coactivators CBP, p300, and PBP differential role in transcriptional regulation JOURNAL OF BIOLOGICAL CHEMISTRY Misra, P., Qi, C., Yu, S. T., Shah, S. H., Cao, W. Q., Rao, M. S., Thimmapaya, B., Zhu, Y. J., Reddy, J. K. 2002; 277 (22): 20011-20019

    Abstract

    PIMT (PRIP-interacting protein with methyltransferase domain), an RNA-binding protein with a methyltransferase domain capable of binding S-adenosylmethionine, has been shown previously to interact with nuclear receptor coactivator PRIP (peroxisome proliferator-activated receptor (PPAR)-interacting protein) and enhance its coactivator function. We now report that PIMT strongly interacts with transcriptional coactivators, CBP, p300, and PBP but not with SRC-1 and PGC-1alpha under in vitro and in vivo conditions. The PIMT binding sites on CBP and p300 are located in the cysteine-histidine-rich C/H1 and C/H3 domains, and the PIMT binding site on PBP is in the region encompassing amino acids 1101-1560. The N-terminal of PIMT (residues 1-369) containing the RNA binding domain interacts with both C/H1 and C/H3 domains of CBP and p300 and with the C-terminal portion of PBP that encompasses amino acids 1371-1560. The C-terminal of PIMT (residues 611-852), which binds S-adenosyl-l-methionine, interacts respectively with the C/H3 domain of CBP/p300 and with a region encompassing amino acids 1101-1370 of PBP. Immunoprecipitation data showed that PIMT forms a complex in vivo with CBP, p300, PBP, and PRIP. PIMT appeared to be co-localized in the nucleus with CBP, p300, and PBP. PIMT enhanced PBP-mediated transcriptional activity of the PPARgamma, as it did for PRIP, indicating synergism between PIMT and PBP. In contrast, PIMT functioned as a repressor of CBP/p300-mediated transactivation of PPARgamma. Based on these observations, we suggest that PIMT bridges the CBP/p300-anchored coactivator complex with the PBP-anchored coactivator complex but differentially modulates coactivator function such that inhibition of the CBP/p300 effect may be designed to enhance the activity of PBP and PRIP.

    View details for DOI 10.1074/jbc.M201739200

    View details for Web of Science ID 000175894800101

    View details for PubMedID 11912212

Stanford Medicine Resources: